Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00BTW
|
|||
| Former ID |
DIB010847
|
|||
| Drug Name |
UC-781
|
|||
| Synonyms |
Thiocarboxanilide; UC-040; UC-10; UC-82; Oxathiin carboxanilide analogs, Biosyn/CONRAD; UC analogs, Biosyn/CONRAD; Oxathiin carboxanilide analogs, Uniroyal/NCI/Southern Research Institute; UC analogs, Uniroyal/NCI/Southern Research Institute
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1], [2] | |
| Company |
Biosyn
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H18ClNO2S
|
|||
| Canonical SMILES |
CC1=C(C=CO1)C(=S)NC2=CC(=C(C=C2)Cl)OCC=C(C)C
|
|||
| InChI |
1S/C17H18ClNO2S/c1-11(2)6-8-21-16-10-13(4-5-15(16)18)19-17(22)14-7-9-20-12(14)3/h4-7,9-10H,8H2,1-3H3,(H,19,22)
|
|||
| InChIKey |
YZHIXLCGPOTQNB-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 178870-32-1
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00441909) Phase I Study of Safety and Persistence of UC-781 Vaginal Microbicide. U.S. National Institutes of Health. | |||
| REF 2 | First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy. PLoS One. 2011;6(9):e23243. | |||
| REF 3 | The nonnucleoside reverse transcriptase inhibitor UC-781 inhibits human immunodeficiency virus type 1 infection of human cervical tissue and dissemination by migratory cells. J Virol. 2005 Sep;79(17):11179-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.